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It has been suggested that neuroleptic medication may decrease cancer risk. We compared cancer risks in a population-based cohort
study of 25264 users (X2 prescriptions) of neuroleptic medications in the county of North Jutland, Denmark, during 1989–2002,
with that of county residents who did not receive such prescriptions. Statistical analyses were based on age-standardisation and
Poisson regression analysis, adjusting for age, calendar period, COPD, liver cirrhosis or alcoholism, use of NSAID, and, for breast
cancer, additionally for use of hormone therapy, age at first birth, and number of children. Use of neuroleptic medications was
associated with a decreased risk for rectal cancer in both women and men (adjusted IRRs of 0.61 (95% confidence interval, 0.41–
0.91) and 0.82 (0.56–1.19), respectively) and for colon cancer in female users (0.78; 0.62–0.98). Some risk reduction was seen for
prostate cancer (0.87; 0.69–1.08), but breast cancer risk was close to unity (0.93; 0.74–1.17). Overall, treatment with neuroleptic
medications was not related to a reduced risk of cancer, but for cancers of the rectum, colon and prostate there were suggestive
decreases in risk.
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Neuroleptic medications, in the form of chlorpromazine and other
phenothiazine compounds, were introduced into clinical psychia-
try in the 1940s and 1950s, and it was proposed early on that these
medications might be associated with a reduced cancer risk (Jones,
1985). A recent review concluded that phenothiazines seem to have
antiproliferative effects on many tumour cell lines in vitro
correlating with an antagonistic effect on calmodulin activity,
suggesting that calmodulin could be the intracellular target of
phenothiazine-induced cell growth inhibition (Hait and Lazo,
1986; Nordenberg et al, 1999).
Neuroleptics have been hypothesised to account for the reduced
cancer occurrence observed in patients with schizophrenia in a
number of studies (Dupont et al, 1986; Mortensen, 1989; Gulbinat
et al, 1992; Mortensen, 1994; Lichtermann et al, 2001; Dalton et al,
2005). This reduction has been found primarily in men in
smoking-related cancers, and in prostate and rectal cancer. Except
for a nested case–control study of prostate cancer among Danish
schizophrenic in-patients that showed a reduced risk after
treatment with chlorpromazine or other high-dose phenothiazines
(Mortensen, 1992), the cohort studies of cancer incidence in
schizophrenic patients have not included information on use of
specific medications.
By contrast, concern has been raised that neuroleptic medica-
tion may increase breast cancer risk due to their prolactin-
increasing effect (Schyve et al, 1978) and this has been reported
among women with schizophrenia (Nakane and Ohta, 1986;
Gulbinat et al, 1992; Lichtermann et al, 2001) and a range of
psychiatric disorders (Halbreich et al, 1996; Wang et al, 2002). The
few studies of breast cancer risk in patients treated with
neuroleptics have mainly found no excess (Overall, 1978; Wagner
and Mantel, 1978; Kanhouwa et al, 1984; Kelly et al, 1999), an
exception being a recent cohort study (Wang et al, 2002).
We examined risks for cancer overall and for specific sites
among adult users of neuroleptic medication in a population-
based cohort study of all residents in a Danish county during a
14-year period.
MATERIALS AND METHODS
The study was conducted within the population of North Jutland, a
Danish county with 500000 inhabitants. The Danish National
Health Service provides tax supported health care for all
inhabitants, guaranteeing free access to general practitioners and
hospitals, and refunds parts of the costs of drugs prescribed by
physicians (Olivarius et al, 1997). All services are registered by use
of the personal identification number, which is assigned to all
Danish citizens by the Central Population Register (CPR) and
encodes gender and date of birth. Use of the personal identification
number secures valid linkage between population-based registries
and allows for the establishment of complete cancer and
prescription histories for each individual.
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From the files of the CPR, we identified all 463232 inhabitants of
North Jutland County on 1 January 1989, who were 16–85 years of
age during the period 1 January 1989–31 December 2002. We
excluded 14249 individuals with a history of cancer (except
nonmelanoma skin cancer) prior to study entry (1989 or age 16
years) by linkage to the nation-wide Danish Cancer Registry,
leaving 448983 persons for follow-up. The Danish Cancer Registry
has recorded incident cases of cancer on a nation-wide basis since
1943 and has been shown to have accurate and virtually complete
ascertainment of cancer cases (Storm et al, 1997).
Drug exposure data
The North Jutland Prescription Database, established in 1989,
holds key information about all prescriptions for refundable drugs
dispensed from pharmacies in the county (Gaist et al, 1997;
Nielsen et al, 1997). The data include type of drug prescribed
according to the Anatomical Therapeutical Chemical (ATC)
classification system, date of dispensing at the pharmacy, and
the patient’s personal identification number. Using the Prescrip-
tion Database, we identified 25264 individuals in the study
population who received at least two prescriptions for neuroleptic
medication (ATC code N05A) between 1 January 1989 and 31
December 2002 and who were free of cancer at date of second
prescription. Persons with only one prescription for neuroleptic
medication (N¼10877) were not included in this study. ATC code
N05A covers the main neuroleptic categories, including pheno-
thiazines, thiozanthenes, butyrophenones, diazepin-oxazepines,
benzamides, diphenylbutylpiperidines and indol.
Psychiatric diagnosis data
The Psychiatric Case Register is a national register that has been
computerised since 1 April 1969 and contains data on all
admissions to Danish psychiatric in-patient facilities and, since
1995, information from outpatient contacts (Munk-Joergensen and
Mortensen, 1997). There is no fee for psychiatric treatment in
Denmark, and no private psychiatric facilities exist. The diagnostic
system used during the study period was the International
Classification of Diseases, eighth revision (ICD-8) up to 1993 and
10th revision (ICD-10) thereafter. Using the files of the Psychiatric
Case Register, we identified all admissions for psychiatric
disorders in the study population from 1969 through 2001.
Patients with any hospitalisation or outpatient contact for
schizophrenia were identified by ICD-8 code 295 and ICD-10
codes F20 and F25. All other psychiatric in- or outpatients were
grouped together.
Data on other potential confounders
The county Hospital Discharge Registry (HDR) was established in
1977 and contains information on all hospitalisations in the
county, including hospital and department number, dates of
admission and discharge, and up to 20 diagnoses per hospitalisa-
tion and up to six operations per diagnosis (Andersen et al, 1999).
Diagnoses are coded according to a Danish five-digit version of
ICD-8 and ICD-10. We obtained information on all hospitalisa-
tions for chronic obstructive pulmonary disorder (COPD) (ICD-8,
490-492; ICD-10, J40-44), liver cirrhosis (ICD-8, 571,573; ICD-10,
K70, K72, K74, K76) and alcoholism (ICD-8, 303; ICD-10, F10)
between 1978 and 2002, as proxy measures for smoking habits and
alcohol consumption that might confound the relationship
between use of neuroleptic medications and cancer risk.
From the North Jutland Prescription Database, we further
obtained prescription data for medications that potentially could
confound the association between neuroleptic medication and
cancer risk, including nonsteroidal anti-inflammatory drugs
(NSAIDs) (ATC codes; M01A; N02BA01; N02BA51, and
B01AC06) and hormone therapy (HT) (ATC groups: G03A-D and
G03F).
For a subcohort, we obtained information on age at first
childbirth and parity through linkage with the CPR. This
information was available for all women born after 1935 and alive
in 1968 or later. This restricted the base population in this analysis
to 159942 women and the exposed cohort to 6693 women.
Follow-up for cancer
Using information from the Cancer Registry and CPR, all
individuals in the study population were followed through 31
December 2002 for any first primary diagnosis of cancer from 1
January 1989 or age 16 years, whichever occurred later, and
continued until date of cancer diagnosis (except nonmelanoma
skin cancer), death, emigration from North Jutland, or 31
December 2002, whichever came first. The person-time of the
study subjects was distributed according to use of neuroleptic
medication in exposed time (X2 prescriptions for neuroleptic
medication) and unexposed time (no recorded prescriptions for
neuroleptic medication). Person-time between first and second
prescription for neuroleptic medication was excluded from the
analyses. The exposed time was stratified into number of
prescriptions (2–4, 5–9, 10–19, and 20 or more prescriptions).
Statistical analyses
We computed age- and gender-standardised incidence rates for the
exposed group (neuroleptic medication users) by applying direct
standardisation in gender-specific 10-year age groups to the age
distribution of the entire study population (base population). Age-
and gender-standardised incidence rate ratios (IRR) were calcu-
lated by dividing cancer incidence rates for neuroleptic users by
cancer incidence rates for nonusers of neuroleptic medications
(never users). Log-linear Poisson regression analysis, with the
logarithm of person-years at risk as an offset variable, was used to
compute rate ratios adjusted for calendar period (1989–1994,
1995–1999, 2000–2002), age (16–29, 30–39, 40–49, 50–59,
60–69, 70–84 years), hospitalisations for COPD, liver cirrhosis
or alcoholism, and ever use of NSAID. Further, for the subcohort
analysis of female breast cancer risk, the rate ratios were adjusted
for ever use of HT and for number of children and age at first birth
as linear covariates.
Stratified analyses were performed according to sex, number of
prescriptions, years of follow-up and psychiatric disorders.
Subjects were allowed to change between categories of covariates
and exposure variables over time. Within each categorical level all
variables were treated as time independent. A test for linear trend
was used to evaluate dose response with number of prescriptions
and years of follow-up. The statistical analyses were performed in
SAS 8.02.
RESULTS
Characteristics of the cohort of 25264 neuroleptic users are
presented in Table 1. In total, the users of neuroleptic medication
accrued 161478 person-years with a mean follow-up of 6.4 years
(range 0–14 years). Compared with female users, more male users
were diagnosed with schizophrenia and had a diagnosis of COPD
or alcoholism. About a third of the exposed group received 20 or
more prescriptions for neuroleptic medication during the study
period. The cohort of neuroleptic users overall had a high
frequency of psychiatric in- or outpatient contacts, with 6% being
hospitalised with schizophrenia and 31% with other psychiatric
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with heavy smoking (11%) and alcohol use (9%).
The mean age of the subcohort of 6693 women included in the
analysis of breast cancer risk was 43.3 years at entry and mean
follow-up was 7.8 years (data not shown). Among these female
neuroleptic users, 8.5% had a diagnosis of schizophrenia and a
further 33.2% had been hospitalised with another psychiatric
disorder (data not shown).
The age- and gender-standardised incidence rate of cancer
overall was 626 per 100000 person-years among neuroleptic users
and 543 per 100000 person-years among never users, yielding an
incidence rate ratio (IRR) of 1.15 (95% CI, 1.10–1.21) (Table 2).
An increased IRR was observed for lung cancer in both male and
female users, whereas a decreased risk was observed for rectal
cancer and colon cancer in female users and for rectal cancer in
male users (although these latter two risk estimates failed to reach
statistical significance). For prostate and breast cancer, age-
standardised IRRs were close to unity, however, when restricting
the analysis to persons below 67 years of age the IRR for breast
cancer went from 1.07 (95% CI, 0.95–1.21) to 0.92 (95% CI, 0.73–
1.14) (Table 2). Adjustment for calendar period, diagnoses of
COPD, liver cirrhosis, alcoholism, and use of NSAIDs reduced the
risk for total cancer and most dramatically for lung cancer in both
men and women. The IRR for prostate cancer was also reduced
(IRR, 0.87; 95% CI, 0.69–1.08) but the risk estimates for colon or
rectal cancer did not change materially; however, the reduced risk
for colon cancer in female users reached statistical significance
(Table 2). When stratified by type of psychiatric disorder, the rate
ratios for prostate cancer and rectal cancer were similarly reduced
among patients with schizophrenia, patients with other psychiatric
disorders and never hospitalised users of neuroleptic medication
(data not shown). For breast cancer, adjustment for parity, age at
first birth and use of HT did not change the risk estimate in the
subcohort aged 16–66 years. Excluding the first year of follow-up
after second prescription for neuroleptic medication yielded
similar overall results (data not shown).
There were no significant trends in the adjusted rate ratios by
neither number of prescriptions or years of follow-up for cancers
of the lung, rectum, colon, prostate or breast, respectively,
although the risk estimates were generally increased (lung cancer)
or reduced (rectal, colon, prostate and breast cancer) across
all strata (data not shown). In persons with more than 10
Table 1 Characteristics at entry of 25264 adult users of neuroleptic medication in the County of North Jutland, Denmark, 1989–2002
Total Male Female
Characteristics No. % No. % No. %
Total 25264 100 9708 100 15556 100
Mean age at entry
a (years) 58.7 57.3 59.6
Total follow-up (years) 161478 56839 104639
Mean follow-up (years) 6.4 5.9 6.7
Age at entry
a (years)
15–29 1672 7 868 9 804 5
30–39 2645 10 1131 12 1514 10
40–49 3950 16 1523 16 2427 16
50–59 4111 16 1476 15 2635 17
60–69 4537 18 1616 17 2921 19
70–85 8349 33 3094 32 5255 34
Year of first prescription
1989–94 16735 66 6036 63 10699 69
1995–99 5630 22 2411 25 3219 21
2000–02 2899 11 1261 13 1638 11
Number of recorded prescriptions of N05A
2–4 8927 35 3582 37 5345 34
5–9 4543 18 1804 19 2739 18
10–19 3726 15 1391 14 2335 15
20+ 8068 32 2931 30 5137 32
Psychiatric diagnosis
Schizophrenia
b 1547 6 808 8 739 5
Other
c 7788 31 2971 31 4817 31
Never 15929 63 5929 61 10000 64
Diagnosis of COPD
d 2839 11 1280 13 1559 10
Diagnosis of liver cirrhosis
e 472 2 223 2 249 2
Diagnosis of alcoholism
f 1800 7 1118 12 682 4
Use of other drugs
g
Use of NSAID
h 17347 69 6196 64 11151 72
Use of HT
i 4786 19 22 o1 4764 31
Neuroleptic medication, ATC NO5A.
aDate of second prescription.
bSchizophrenia, ICD-8: 295; ICD-10: F20, F25.
cOther, hospitalisation with all other psychiatric diagnosis.
dCOPD, Chronic obstructive pulmonary disease, ICD-8: 490–492; ICD-10: J40–44.
eLiver cirrhosis, ICD-8: 571,573; ICD-10: K70, K72, K74, K76.
fAlcoholism, ICD-8: 303; ICD-
10: F10.
gTwo or more prescriptions prior to censoring events.
hNonsteroidal anti-inflammatory drugs, NSAID, ATC M01A; N02BA01, N02BA51, B01AC06.
iHormone therapy,
HT, ATC G03A, G03C, G03D, and G03F.
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was observed for rectal cancer (IRR, 0.47; 95% CI, 0.18–1.26 in
men and IRR, 0.33; 95% CI, 0.12–0.88 in women) and for prostate
cancer (IRR, 0.66; 95% CI, 0.40–1.10) (data not shown).
DISCUSSION
We found a reduced risk of rectal cancer in both men and women
as well as indications of a reduced risk of colon cancer and
prostate cancer in this population-based cohort of neuroleptic
users, thus providing some support to the hypothesis of an
anticarcinogenic effect of these medications. Reassuringly, we
observed no increased risk for breast cancer in female users.
The hypothesis of an anticarcinogenic effect of neuroleptic
medications is supported mainly by observations of reduced risks
of several cancer types among schizophrenic patients (Dupont
et al, 1986; Mortensen, 1989; Gulbinat et al, 1992; Mortensen,
1994). In this study, we investigated this hypothesis not only
among schizophrenic patients but also among other patients
receiving antipsychotic treatment. Our cohort study had the
advantage of collecting information from population-based
databases and registers with prospectively registered and virtually
complete data on drug prescriptions, psychiatric and somatic
hospital admissions and cancer diagnoses, thus minimising the
possibility of selection and information bias. As neuroleptic
medications are available only by prescription in Denmark, we
are likely to have identified virtually all users of neuroleptic
medications in the study population. The fact that a large
proportion (37%) of the exposed group had been hospitalised
with a psychiatric disorder might have led to some degree of
misclassification in the analyses stratified by number of prescrip-
tions, as these patients were probably treated with neuroleptic
medication during their hospital admissions, information to which
we had no access. Patients with chronic disorders such as
psychiatric disorders are likely to be under closer medical
supervision and diagnostic activity than the general population
possibly resulting in surveillance bias. Conversely, under-ascer-
tainment of cancer among those who are psychotic due to altered
perception of physical symptoms and lower degree of adherence
to diagnostic activities should also be considered. Although
decreased surveillance cannot be ruled out, Danish autopsy studies
do not support underdiagnosis of cancers in schizophrenic
patients (Mortensen, 1987; Mortensen, 1994).
We observed a decreased risk for rectal cancer in both male and
female users of neuroleptic medication. Although there was no
clear trend by number of prescriptions or length of follow-up, risk
was further reduced among long-term users with more than 10
prescriptions. Studies of patients with schizophrenia in Denmark
and Finland have reported reduced risks for rectal cancer
but not for colon cancer (Mortensen, 1989; Gulbinat et al, 1992;
Mortensen, 1994; Lichtermann et al, 2001; Dalton et al, 2005)
whereas we additionally observed a reduced incidence of
colon cancer among female users of neuroleptic medication in
the present study. Established risk factors for rectal and colon
cancer are similar and we would expect exposure to mutual
risk factors, such as high intake of alcohol, little exercise and
high intake of meat or low intake of vegetables (Potter, 1999),
to be more frequent among our cohort of neuroleptic users.
Use of NSAIDs was frequent in the present cohort of neuroleptic
users, although adjusting for this well established protective
factor in colorectal cancer (Thun et al, 2002; Baron, 2003)
did not alter the risk estimates associated with neuroleptic
medication. In schizophrenia, the hypothesis of a lowered
host susceptibility to cancer in general has been raised (Catts
and Catts, 2000) but the present study indicated that the reduced
risk for rectal cancer was not confined to patients with
schizophrenia.
Table 2 Adjusted incidence rate ratios for selected cancer sites among adult users of neuroleptic medication in the County of North Jutland, Denmark,
1989–2002
Neuroleptic use
a (n¼25264) Never neuroleptic use
b (n¼448983)
Number of cases
Age-standardised
incidence rate
c Number of cases
Age-standardised
incidence rate
d
Age-standardised
incidence rate ratio (CI)
Adjusted incidence
rate ratio (CI)
e
All sites 1648 626 23110 543 1.15 (1.10–1.21) 0.99 (0.94–1.04)
Men 622 626 11531 529 1.18 (1.09–1.28) 1.03 (0.95–1.12)
Women 1026 626 11579 558 1.12 (1.05–1.19) 0.99 (0.93–1.06)
Lung 308 118 3222 76 1.57 (1.40,1.75) 1.24 (1.10–1.40)
Men 127 128 1984 91 1.40 (1.17–1.67) 1.09 (0.91–1.31)
Women 181 109 1238 60 1.81 (1.56–2.10) 1.36 (1.16–1.60)
Colon 139 46 2062 49 0.94 (0.79–1.11) 0.88 (0.74–1.05)
Men 56 49 977 45 1.09 (0.82–1.41) 1.10 (0.84–1.44)
Women 83 43 1085 53 0.81 (0.65–1.01) 0.78 (0.62–0.98)
Rectum 56 20 1198 28 0.71 (0.54–0.92) 0.70 (0.53–0.92)
Men 29 27 724 33 0.80 (0.54–1.15) 0.82 (0.56–1.19)
Women 27 13 474 23 0.57 (0.38–0.83) 0.61 (0.41–0.91)
Breast
f 258 155 3022 145 1.07 (0.95–1.21) 1.06 (0.93–1.21)
Breast
g 83 89 1510 97 0.92 (0.73–1.14) 0.93 (0.74–1.17)
Prostate
h 83 119 1595 124
i 0.96 (0.77–1.19) 0.87 (0.69–1.08)
aTwo or more prescriptions for neuroleptic medication redeemed.
bNo prescription for neuroleptic medication redeemed.
cAnalyses were based on 56839 person-years of
follow-up in men and 104639 person-years of follow-up in women.
dPerson-years of observation: 2198464 in men and 2106003 in women.
eAdjusted for age, calendar period
and diagnosis of COPD, liver cirrhosis, alcoholism and ever use of NSAID.
fAdjusted for age, calendar period and diagnosis of COPD, liver cirrhosis, alcoholism, ever use of
NSAID and HT.
gAdjusted for age, calendar period and diagnosis of COPD, liver cirrhosis, alcoholism, ever use of NSAID, age at first child birth, number of children and ever use
of HT; This analysis was based on 52418 women-years of follow-up.
hRestricted to men above 40 years of age, based on 47603 men-years of follow-up.
iPerson-years of
observation: 1287640.
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reported in patients with schizophrenia (Mortensen, 1989;
Mortensen, 1994; Lichtermann et al, 2001; Dalton et al, 2005)
and the finding of a reduced risk among men with schizophrenia
treated with high-dose phenothiazines (IRR, 0.33; 95% CI, 0.12–
0.94) in a small Danish case–control study (Mortensen, 1992).
Although in the present study there was no clear trend by number
of prescriptions or length of follow-up we did find a 44% lower risk
among long-term users with multiple prescriptions. Further, the
reduced risk estimates were not confined to patients with
schizophrenia but observed in all groups of users of neuroleptic
medication, thus supporting an effect of the neuroleptic medica-
tion, rather than of schizophrenia.
A rationale for any association between use of neuroleptic
medications and breast cancer is that conventional antipsychotic
agents inhibit dopamine action at D2 receptors, leading to
hyperprolactinemia (Halbreich et al, 2003). Epidemiological
studies have produced inconsistent findings (Overall, 1978; Schyve,
1978; Wagner & Mantel, 1978; Kanhouwa et al, 1984; Nakane et al,
1986; Gulbinat et al, 1992; Halbreich et al, 1996; Lichtermann et al,
2001), although a more recent cohort study reported a relative risk
of 1.16 (95% CI, 1.07–1.26) for breast cancer associated with use of
neuroleptic medication, as well as a positive dose–response
relationship (Wang et al, 2002). This study included information
on a number of factors not included in previous studies, but
residual confounding by factors such as reproductive history and
family history of breast cancer or incomplete information on
socioeconomic status and exogenous hormone use cannot be ruled
out (Wang et al, 2002). In the present study, we were able to adjust
for reproductive factors and use of HT and we found no evidence
for an increased breast cancer risk.
Finally, our finding of an increased risk for lung cancer likely
reflects the increased smoking among individuals with psychiatric
disorders and in treatment with neuroleptic medication. We were
able to include certain hospital diagnoses as proxies for heavy
smoking and alcohol use; however, given the extent of evidence
documenting the increased prevalence of smoking and alcohol use
in long-term psychiatric patients (O’Farrell et al, 1983; Hughes
et al, 1986; de Leon et al, 1995; Lasser et al, 2000), we believe that
our results for lung cancer reflect residual confounding by
smoking. In support of this, we also observed an increased
risk for other smoking related cancers combined, that is cancer
of the buccal cavity, oesophagus, pancreas, larynx, urinary
bladder, and kidney (Dreyer et al, 1997) (adjusted IRR, 1.15;
95% CI, 0.97–1.37) among male users of neuroleptic medications
(data not shown).
In conclusion, although no overall decrease in cancer incidence
was found, the results of this study provide some support for an
anticarcinogenic effect of neuroleptic use for cancers of the
rectum, colon and prostate. Reassuringly, we found no increased
risk for breast cancer.
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